Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor belonging to the bHLH/PAS superfamily. It plays a crucial role in sensing environmental chemicals (xenobiotics) and endogenous metabolites, regulating gene expression in response. Upon ligand binding, AhR translocates to the nucleus, dimerizes with ARNT, and binds to XRE/DRE sequences, modulating the transcription of target genes involved in xenobiotic metabolism, immune function, development, and other processes. Dysregulation of AhR is implicated in various diseases, including immunotoxicity, cancer, and developmental abnormalities.
Ligand binding to AhR induces a conformational change, leading to dissociation from chaperone proteins (Hsp90, XAP2/AIP/ARA9, p23), translocation to the nucleus, dimerization with ARNT, binding to XRE/DRE sequences on DNA, and regulation of target gene transcription (e.g., CYP1A1, CYP1B1).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aryl hydrocarbon receptor (AhR).